[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Gødstrup Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":376},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,76,111,132,162,191,218,245,275,308,329,346],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100623773","restrictive-versus-liberal-fluid-intake-in-acute-decompensated-heart-failure-100623773",false,"NCT07400991","Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure","Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure: a Randomized Trial","RELIEF-AHF","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Hospitalized for ADHF as the primary diagnosis, meeting both of the following:\n\n   1. ≥1 documented symptom of new or worsening heart failure (dyspnea, fatigue, decreased exercise tolerance, or symptom of end-organ hypoperfusion).\n   2. Objective evidence of ADHF, defined as either:\n\n   i. ≥2 physical signs (edema, ascites, pulmonary rales\u002Fcrackles, increased JVP, S3 gallop, rapid weight gain due to fluid retention), OR ii. ≥1 physical sign AND ≥1 laboratory finding indicative of ADHF (BNP \\>500 ng\u002FL or NT-proBNP \\>2000 ng\u002FL if sinus rhythm, or BNP \\>750 ng\u002FL or NT-proBNP \\>3000 ng\u002FL if atrial fibrillation, radiological\u002Fultrasound evidence of pulmonary congestion, echocardiographic sign \\[VCI \\>2.1 cm, LVOT VTI \\\u003C15 cm, E\u002Fe' \\>14, D-dominant pulmonary venous inflow pattern\\], or invasive evidence \\[CVP \\>12 mmHg, PCWP \\>18 mmHg, CI \\\u003C2.2 L\u002Fmin\u002Fm2\\]).\n3. Treatment with ≥40 mg IV furosemide (or equivalent)\n4. Enrolment within 24 hours of admission\n5. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Requirement at admission for ICU-level care, or IV inotropic\u002Fvasopressor therapy for ADHF.\n2. Na+ \\\u003C125 mmol\u002FL or Na+ \\>145 mmol\u002FL.\n3. End-stage chronic kidney disease on chronic dialysis or eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m2\n4. Any condition which would make participation unsafe or substantially affect protocol adherence, as judged by investigator.","ALL","18 Years",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this clinical trial is to learn whether a thirst-driven, liberal fluid-intake strategy is comparable to a fluid-restriction strategy in patients hospitalized for acute decompensated heart failure (ADHF). The study will also assess the safety of the intervention and its effects on thirst and quality of life.\n\nPatients hospitalized with ADHF will be asked to follow either a thirst-driven fluid-intake strategy or a fluid-restriction strategy during their hospital stay and for one month after discharge.",[27],"Acute Heart Failure (AHF)",[29,30,31,32,33],"Fluid Restriction","Thirst-driven fluid intake","Liberal fluid intake","Acute heart failure","Time to clinical stability","RECRUITING","2026-05-04",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":38},"2026-05-01",{"date":42,"type":21},"2029-08",{"name":44,"class":45},"Gødstrup Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100636881","phase-4-cardiologist-administered-midazolam-vs-anaesthesiologist-assisted-propofol-sedation-for-transoesophageal-echocardiography-guided-cardioversion-of-atrial-fibrillation-100636881","NCT07571447","Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation","Cardiologist-Administered Midazolam vs. Anaesthesiologist-Assisted Propofol Sedation For Transoesophageal Echocardiography-Guided Cardioversion of Atrial Fibrillation (CARDIOZOLAM-1)","CARDIOZOLAM-1","Inclusion Criteria:\n\n* Adult patients (≥18 years) with atrial fibrillation or flutter\n* Scheduled for transoesophageal echocardiography-guided direct current cardioversion\n\nExclusion Criteria:\n\n1. Previous enrolment in the trial\n2. Expected prolonged hospitalisation (\\>8 hours) despite sinus rhythm restoration:\n\n   * Ongoing medical needs after cardioversion (e.g., decompensation or infection)\n   * Planned procedures after cardioversion (same-day TTE or pacemaker test allowed)\n   * Social barriers for same-day discharge\n3. Indication for anaesthesiology assistance:\n\n   * Haemodynamic instability (systolic blood pressure \\\u003C90 mmHg)\n   * Known severe pulmonary disease (FVC or FEV1 \\\u003C50% predicted)\n   * Body mass index \\>40 kg\u002Fm2\n   * Previous complications or allergic reactions to sedation\n4. Contraindications:\n\n   * Pregnant or breastfeeding\n   * Intracardiac thrombus\n   * Total benzodiazepine dose used for TOE \\>20 mg\n\nAbbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.",{"count":56,"type":21},220,[58],"PHASE4","Irregular heart rhythms, known as atrial fibrillation or atrial flutter, are common conditions that can increase the risk of stroke and heart failure. A standard treatment to restore a normal rhythm is a controlled electric shock, known as cardioversion. However, if the irregular rhythm has lasted more than 24 hours, if the duration is uncertain, and if the patient has not been on blood-thinning medication for at least three weeks, doctors must first check for blood clots in the heart. This is done using a special ultrasound scan of the heart through the food pipe.\n\nBoth the scan and the electric shock treatment require sedation to make the patient relaxed or asleep. The scan uses mild sedation from a cardiologist, while the shock needs a stronger sedative given by an anaesthesiologist. But needing this extra doctor can cause delays, so patients often wait longer for treatment and to go home.\n\nThis study will test whether a cardiologist can safely handle both steps using a sedative called midazolam. This study will include 220 adults at multiple hospitals in Denmark and compare this new approach to standard care. Researchers will track how quickly patients go home, how well the treatment works, any serious side effects, what patients think about the experience, and how much money can be saved.\n\nIf proven safe and effective, this new method could reduce treatment delays, shorten hospital stays, and lower healthcare costs-ultimately improving care for patients and making the healthcare system more efficient.",[61,62],"Atrial Fibrillation (AF)","Atrial Flutter",[64,65],"Direct current cardioversion","Transoesophageal echocardiography","NOT_YET_RECRUITING","2026-04-30",{"date":69,"type":38},"2026-05-06",{"date":71,"type":21},"2026-05",{"date":73,"type":21},"2027-05",{"name":44,"class":45},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100615172","pediatric-anesthesia-the-childs-voice-100615172","NCT07289152","Pediatric Anesthesia: The Childs Voice","Pediatric Health Empowerment: Improving Children´s Perioperative Experiences With Patient-Reported Measures","PHEASE","Inclusion Criteria:\n\n* Pediatric patients aged 4-12, American Society of\n* Anesthesiologists physical status classification (ASA) I-III\n* undergoing surgery\n\nExclusion Criteria:\n\n* Children with cognitive or sensory disorders\n* children or parents who do not speak Danish,\n* patients for whom there is no consent to participate.","4 Years","12 Years",{"count":87,"type":21},250,"OBSERVATIONAL","In Denmark, around 25,000 children under 18 undergo general anesthesia annually. Hospital stays and anesthesia can induce significant anxiety and stress in children due to unfamiliar environments, procedures, and communication issues. This anxiety can be linked to postoperative complications such as emergence delirium and may negatively impact both the child and their family's well-being. Engaging patients actively in their healthcare, including pediatric cases, is essential for improving outcomes. Assessing perioperative patient and family outcomes, particularly through patient-reported outcome measures (PROM) and patient-reported experience measures (PREM), can significantly enhance the quality of care provided to children. While PROMs are widely used in adults, they are less common in pediatric settings. The Pediatric Scale for Quality of Recovery (PedSQoR), developed by Australian and American researchers, is one such tool designed to measure recovery in children. This study aims to translate andvalidate the PedSQoR for Danish children aged 4-12. Furthermore, no existing instruments comprehensively assess pediatric surgery patients' experiences under general anesthesia, particularly from the child's perspective without relying on parents as proxies. Empowering children to express their healthcare experiences gives healthcare workers an insight into what matters for children and gives children a more positive outlook on healthcare, benefiting lifelong engagement.\n\nStudy Aims and Objectives: The study aims to enhance the assessment of children's outcomes and experiences in perioperative settings, ultimately improving pediatric perioperative healthcare. The objectives include:\n\n1. Translation and Adaptation: a. Translate and adapt the PedSQoR for Danish children aged 4-12. b. Validate the Danish PedSQoR version.\n2. Development of a PREM Instrument: a. Develop a comprehensive PREM for children's experiences during surgery and anesthesia. b. Pilot-test and adjust the PREM questionnaire with a group of children aged 4-12.\n\nStudy Methods:\n\n1. PedSQoR Translation and Validation:\n\n   A single-center prospective cohort study will adapt and test the PedSQoR for Danish children. The process involves translating the 21-item scale, validating it with a sample size of 150, and ensuring reliability through various statistical methods, including Cronbach's Alpha and test-retest reliability. Data will be collected from the Department of Anesthesiology and Intensive Care at Gødstrup Hospital.\n2. PREM Instrument Development:\n\nThis study will develop a PREM instrument using the Warwick Patient Experiences Framework (WaPEF), which encompasses seven dimensions of patient experience. The process will involve forming a panel of child experts, conducting focus groups, and translating insights into a pictorial questionnaire. The PREM will undergo pilot testing with 20 children to validate its effectiveness in capturing the dimensions of the WaPEF.\n\nResearch Ethics: Given the vulnerability of children in research, this study will prioritize their safety and comfort, ensuring the study's benefits outweigh any potential risks. Informed consent will be obtained from both parents and children. The study will be registered with the Region Central Denmark's list of research projects and will not require approval from the Scientific Ethics Committee.",[91,92,93,94],"Pediatric Anesthesia","Pediatric Surgery","PROMs","PREMs",[96,97,98,99,100,101],"PROM","Patient-reported outcom measues","Children","child","PREM","Patient-reported experience measures","2026-04-22",{"date":104,"type":38},"2026-04-23",{"date":106,"type":38},"2026-01-01",{"date":108,"type":21},"2030-12-31",{"name":44,"class":45},3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100634112","pre-anaesthesia-reviews-in-denmark---status-of-a-person-centred-approach-100634112","NCT07535450","Pre-anaesthesia Reviews in Denmark - Status of a Person-centred Approach","Inclusion Criteria:\n\n* Patients, who can read\u002Fwrite Danish and can give informed consent.\n\nExclusion Criteria:\n\n\\-",{"count":118,"type":21},1000,"The goal of this observational study is to learn about current pre-anaesthesia practices in Denmark and patients' experiences of pre-anaesthesia consultations as well as what matters to patients before anaesthesia.\n\nThe questions the study aims to answer are:\n\nWhat are the current pre-anaesthesia practices in Danish public hospitals. How do patients experience pre-anaesthesia consultations in Danish public hospitals.\n\nWhat matters to patients before anaesthesia in Danish public hospitals.\n\nOn the day of surgery, patients answer an online survey about what matters to them when undergoing anaesthesia and whether they spoke with an anaesthesiologist or nurse anaesthetist about the anaesthesia.\n\nData from the medical chart are obtained to support patients responses. For patients receiving a pre-anaesthesia consultation, we will summarise the degree of person-centredness experienced by patients.",[121],"Anesthesia",[123],"Person-centredness","2026-04-10",{"date":126,"type":38},"2026-04-17",{"date":128,"type":21},"2026-06-01",{"date":130,"type":21},"2026-09-01",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100628262","can-changes-in-dialysate-sodium-concentration-improve-blood-pressure-and-endothelial-function-in-chronic-hd-patients-100628262","NCT07459348","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients?","Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Patients Undergoing Chronic Hemodialysis?","NADI","Inclusion Criteria:\n\n* Adults receiving chronic in-center hemodialysis at Regional Hospital Gødstrup\n* Age ≥ 18 years\n* On thrice-weekly hemodialysis for a stable period (as assessed in EPJ)\n* Plasma sodium within the range required for safe participation (as per screening)\n* Able to understand study information and provide written informed consent\n* Eligible based on review of electronic patient record (dialysis duration, frequency, age, p-sodium)\n\nExclusion Criteria:\n\n* Significant cardiac disease that may interfere with participation, including:\n* Heart failure (with clinically relevant instability)\n* Recent acute myocardial infarction (date verified in EPJ)\n* Pacemaker (specific types that interfere with measurements)\n* History of stroke or TCI (date verified in EPJ)\n* Amputation of an extremity (affects body composition measurements)\n* Diabetes with unstable glycemic control or recent major treatment changes\n* Any condition that prevents accurate blood pressure measurement or CO-rebreathing\n* Inability to complete study procedures (questionnaires, monitoring, blood sampling)\n* Expected inability to complete both intervention periods (e.g., planned transfer, transplantation)\n* Declines participation after receiving oral and written information",{"count":141,"type":21},25,[24],"People with end stage kidney disease cannot regulate salt and water normally, which often leads to high blood pressure, fluid overload, and a higher risk of heart disease.\n\nHemodialysis is a life sustaining treatment that removes waste products, excess fluid, and electrolytes from the blood. However, the treatment itself can influence blood pressure and how the blood vessels function. Many patients experience symptoms such as thirst, headaches, fatigue, and swelling, which affect both daily well being and long term health. One possible way to reduce these problems may be as simple as adjusting the amount of sodium in the dialysis fluid.\n\nDuring dialysis, substances move between the patient's blood and the dialysate, the special fluid used in the machine. Sodium is one of the most important components because it helps regulate fluid balance and blood pressure. A higher sodium concentration in the dialysate can make patients feel more thirsty, cause them to drink more, and lead to fluid retention and higher blood pressure. On the other hand, lowering sodium too much can cause dizziness, low blood pressure, cramps, and discomfort during treatment. Because of this, there is ongoing debate about what the \"right\" sodium level should be.\n\nToo much sodium over time may also harm the blood vessels. The inner lining of the vessels, called the endothelium, is protected by a thin layer known as the glycocalyx. This layer helps prevent sodium from entering the vessel wall and supports the production of nitric oxide, a molecule that relaxes blood vessels and reduces inflammation. High salt exposure can damage the glycocalyx and reduce nitric oxide production, making the vessels stiffer and raising blood pressure. In dialysis patients, low nitric oxide levels are linked to worse outcomes and episodes of rising blood pressure during treatment. Some small studies suggest that lowering dialysate sodium can improve blood pressure and endothelial function, but larger studies have not shown clear effects on survival. This indicates that we still do not fully understand which patients benefit most or how sodium changes affect both physical and subjective symptoms.\n\nThis study aims to fill these knowledge gaps by examining how a lower sodium concentration in the dialysate affects blood pressure, blood vessel function, fluid overload, inflammation, and patient reported symptoms. The goal is to provide new insights that could help tailor dialysis treatment to individual patients in a simple and cost effective way.\n\nThe study will compare two sodium concentrations: a lower level (133 mmol\u002FL) and the standard level used in many clinics (139 mmol\u002FL). Twenty five patients receiving chronic in center hemodialysis will participate. Each patient will undergo both treatments for three weeks each, in random order, with a two week washout period in between. This crossover design allows each patient to serve as their own control, making it easier to detect meaningful differences.\n\nThe main outcome is the difference in 24 hour systolic blood pressure between the two sodium levels. Secondary outcomes include changes in nitric oxide levels in the blood, measures of fluid overload using two different techniques, markers of inflammation, arterial stiffness, and patient reported symptoms such as thirst, fatigue, and overall well being. The study will also compare two methods for assessing fluid overload: bioimpedance spectroscopy and a newer carbon monoxide rebreathing technique.\n\nBlood pressure and arterial stiffness will be measured over 44 hours using a portable device. Blood samples will be collected to analyze nitric oxide, inflammatory markers, and sodium handling in red blood cells. Fluid status will be measured using both bioimpedance and the CO rebreathing method. Patients will complete a weekly questionnaire developed together with dialysis patients to capture their experiences and symptoms.",[145,146,147,148],"Dialysis Dependent Chronic Kidney Disease","Dialysis Patients","Sodium Excess","High Blood Pressure",[150,151,152,153,154],"Dialysate Sodium Concentration","Hemodialysis","Blood Pressure Control","Endothelial Function \u002F Nitric Oxide (NOx)","Fluid Overload Assessment (CO Rebreathing & Bioimpedance)","2026-03-11",{"date":157,"type":38},"2026-03-13",{"date":40,"type":21},{"date":160,"type":21},"2029-12-31",{"name":44,"class":45},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":170,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100555047","genetic-and-epigenetic-background-of-inner-ear-dysfunction-in-turner-syndrome-100555047","NCT06507007","Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner Syndrome","EPIHEAR","Inclusion Criteria:\n\n* age between 18 and 60 years old\n\nExclusion Criteria:\n\n* Contraindications for the MRI or CBCT\n* Serious medical disorders\n* Neurological or psychiatric disorders of any kind\n* Use of medication that is known to influence inner ear function\n* Medical history with dizziness or hearing problems (controls only)",true,"FEMALE","60 Years",{"count":173,"type":21},150,"The goal of this case-control study is to pave the way for new revolutionary treatment measures within hearing loss that could either replace or delay the need for hearing aids. The study focuses on people with Turner syndrome (TS).\n\nThe aim is to find out if there are specific DNA methylation patterns and\u002For RNA expression profiles linked to sensorineural hearing loss (SNHL) in people with TS. Additionally, the structure and function of the inner ear in these individuals will be examined to see if there is a connection to their epigenetic profile.\n\nThe main question it aims to answer is: Does epigenetics constitute a common denominator for some of the unexplained SNHL cases?\n\nTurner Syndrome (TS) represents an ideal model for studying epigenetics related to sensorineural hearing loss (SNHL).\n\nParticipants will undergo the following tests:\n\n* Ear examinations\n* Hearing tests\n* Balance tests\n* Blood tests\n* MRI scans\n* CBCT (cone-beam computed tomography) scans",[176,177,178],"Sensorineural Hearing Loss","Turner Syndrome","Inner Ear Disease",[180,181,177,182],"Epigenetics","Sensorineural hearing loss","Inner Ear Dysfunction","2026-01-24",{"date":185,"type":38},"2026-01-27",{"date":187,"type":38},"2025-02-01",{"date":189,"type":21},"2027-07-30",{"name":44,"class":45},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100615302","the-effects-of-dietary-nitrate-in-patients-with-hypertensive-kidney-injury-100615302","NCT07290842","The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury","DINO-CKD","Inclusion Criteria:\n\n* Hypertension, treated with a maximum of 2 antihypertensive drugs and unattended office BP \\\u003C 150\u002F95 mmHg at the screening visit, or newly diagnosed without antihypertensive treatment by 24-hour BP or home BP measurement (above 130\u002F80 or 135\u002F85 respectively), and unattended office BP \\\u003C 160\u002F100 mmHg.\n\n  * CKD I-III based on hypertensive kidney injury. Patients, who previously met the criteria for CKD I within the last 5 years, but no longer has proteinuria after relevant treatment, can also be included. Diagnosis of CKD I can be based on eGFR and either urine albumin\u002Fcreatine ration or urine-dipstick test with presence of protein.\n  * Albumin\u002Fcreatinine ratio \\\u003C 500 mg\u002Fg\n  * eGFR \\> 30 ml\u002Fmin\u002F1,73m2\n  * Body Mass Index (BMI) ≤ 35 kg\u002Fm2\n  * Able to adhere to dietary regimen\n  * Fertile women must use safe contraception (oral contraceptive pill, hormonal or copper intrauterine device, vaginal ring, contraceptive implant, transdermal contraceptive patch or contraceptive injections) or abstinence. Excluded from this are postmenopausal woman without menstrual bleeding for at least 12 months before inclusion, surgically sterilized women and women with surgically sterilized partner.\n\nExclusion Criteria:\n\n* • Diagnosis of heart failure, NYHA II-IV\n\n  * Diagnosis of liver failure\n  * Diabetes mellitus (all types)\n  * Current malignant disease (other than non-melanoma skin cancer)\n  * Indicators of other aetiologies of CKD than hypertensive kidney injury, e.g. through kidney biopsy or biochemistry.\n  * Previous kidney transplant recipient\n  * History of stroke or transient cerebral ischemic attack\n  * Current indication of untreated cardiovascular disease, e.g. planned work-up for ischemia.\n  * History of myocardial infarction, apart from non-STEMI more than 1 year prior to the study, if the subject is currently revascularized and relevantly medicated.\n\nOrganic nitrate treatment Diagnosed secondary hypertension other than renal parenchymal hypertension (i.e. renal artery stenosis, primary hyperaldosteronism, low renin hypertension etc.)\n\n* Pregnancy or lactation\n* Alcohol abuse (intake above the recommended guidelines from Danish Health Authorities)\n* Conditions treated with medication that investigator finds may interfere with the effect parameters, and cannot be discontinued during the trial (e.g. atrial fibrillation treated with betablockers)\n* If, according to the investigator's assessment, the participant is considered unsuitable to participate.","70 Years",{"count":200,"type":21},20,[24],"The study aims to study the effects of diatery nitrate in patients with hypertension and hypertensive kidney injury.\n\nThe study is a randomized, placebo-controlled, double-blinded crossover trial. 14-20 patients with hypertension and CKD I-III will be randomized to receive either nitrate or placebo delivered in the form of beetroot juice.\n\nEffect variables will be measured before and after a 2 week treatment. After a washout period of 14 days, the subjects are crossed over to the opposite treatment.\n\nThe study is terminated by measuring effect variables after the second treatment period.",[204,205],"Hypertension","CKD - Chronic Kidney Disease",[207,208,209],"nitrate","hypertension","beetroot","2025-12-17",{"date":212,"type":38},"2025-12-18",{"date":214,"type":38},"2025-12-08",{"date":216,"type":21},"2030-01-01",{"name":44,"class":45},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":234,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":46},"100526979","early-nutritional-intervention-in-patients-with-cancer-100526979","NCT06141785","Early Nutritional Intervention in Patients With Cancer","Early Nutritional Intervention to Prevent Malnutrition in Patients With Cancer Receiving Palliative Chemotherapy in an Outpatient Setting","NICOS","Inclusion Criteria:\n\n* patients who are newly diagnosed with lung, colorectal, ovarian, or pancreatic cancer.\n* patients treated with first-line palliative chemotherapy\n* patients who are Danish speaking\n* patients ≥18 years of age\n* patients who are cognitive well-functioning\n\nExclusion Criteria:\n\n* Patients not using electronic mail\n* patients with dementia\n* patients not able to comply with the study protocol",{"count":227,"type":21},200,[24],"The goal of this intervention study is to study the effect of nutritional interventions in patients with cancer receiving palliative chemotherapy. The main question it aims to answer is: Does early nutritional interventions affect body weight, quality of life, survival, muscle mass, performance status, physical function, nutritional risk and treatment tolerance in patients with cancer receiving palliative chemotherapy? Researchers will compare patients receiving the intervention to a historical control cohort following current clinical practice.",[231,232,233],"Nutritional Intervention","Cancer","Malnutrition",[235,236,232,233,237],"Nutritional interventions","Dietetics","Nutrition",{"date":239,"type":38},"2025-12-24",{"date":241,"type":38},"2024-06-01",{"date":243,"type":21},"2027-01-29",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":262,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":46},"100505762","perfusion-estimation-for-optimal-treatment-strategy-in-chronic-coronary-syndrome-100505762","NCT05865600","Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome","Perfusion Estimation for Optimal Revascularization and Medical Therapy in Chronic Coronary Syndrome - a Randomized Trial","PERFORM-CCS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Willing to participate and able to understand, read and sign the informed consent document before the planned procedure\n3. Known ischemic heart disease defined as one of the following\n\n   1. Previous myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting\n   2. Previous coronary computed tomography angiography or invasive coronary angiography documenting atherosclerosis.\n4. Undergoing clinically indicated \\[15O\\]H2O cardiac PET\u002FCT due to chest discomfort or dyspnea as angina equivalent\n\n   Additional inclusion criteria for randomized trial:\n5. Initial \\[15O\\]H2O cardiac PET\u002FCT with abnormal perfusion defined as all of the following\n\n   1. Hyperemic myocardial blood flow (hMBF) ≤2.3 mL\u002Fmin\u002Fg in at least two adjacent myocardial segments\n   2. Relative hMBF ≤ 65% in at least two adjacent segments as compared with the mean hMBF of the two adjacent segments with the highest mean hMBF\n   3. Tissue perfusion defect extent ≥ 5% based on indices of relative hypoperfusion\n6. Clinical indication for invasive coronary angiography decided at a multidisciplinary conference between consultants in nuclear medicine and cardiology\n\nExclusion Criteria:\n\n1. Ongoing acute coronary syndrome or acute coronary syndrome within 30 days\n2. Contraindications for adenosine\n\n   1. Severe asthma\n   2. Advanced atrioventricular block without pacemaker\n   3. Severe aortic stenosis\n3. Patients not able to breath hold (severe COPD\u002Fasthma)\n4. Pregnant women, including women who are potentially pregnant or lactating\n5. Allergy to iomeron\n6. Life expectancy of less than 2 years\n7. Severe valvular disease\n8. Reduced kidney function with an estimated glomerular filtrations rate \\\u003C40 ml\u002Fmin\n9. Inability to consent\n\n   Additional exclusion criteria for randomized trial:\n10. Unprotected left main coronary artery stenosis on coronary CT angiography\n11. Very large perfusion defect on initial \\[15O\\]H2O cardiac PET\u002FCT indicating left main coronary artery stenosis or balanced ischemia defined as tissue perfusion defect extent based on indices of absolute hMBF ≥ 20% in two or more myocardial territories supplied by coronary arteries with an Agatston calcium score ≥ 300",{"count":254,"type":21},570,[24],"We will establish a cohort of 570 symptomatic chronic coronary syndrome patients undergoing 15O-water PET and assess their symptoms through repeated questionnaires. Two hundred patients with abnormal perfusion will be randomized to immediate or delayed referral to invasive coronary angiography with concomitant optimization of guideline-directed medical therapy with repeated 15O-water PET and questionnaires at 3 and 6 months. The primary objective is to compare the potential benefit of early invasive coronary angiography (ICA) versus guideline directed medical therapy (GDMT) on symptomatic relief defined as freedom of angina after 3 months following a positive \\[15O\\]H2O cardiac PET\u002FCT in patients with symptomatic chronic coronary syndrome.",[258,259,260,261],"Chronic Coronary Syndrome","Myocardial Ischemia","Stable Angina","Coronary Artery Disease",[259,263,261,264,265,266],"Angina Pectoris","Coronary Angiography","Computed Tomography Angiography","Myocardial Perfusion Imaging","2025-12-03",{"date":269,"type":38},"2025-12-10",{"date":271,"type":38},"2023-05-23",{"date":273,"type":21},"2027-09-01",{"name":44,"class":45},{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":169,"sex":17,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":46},"100533739","normative-data-of-vestibular-and-postural-function-in-danish-children-100533739","NCT06229730","Normative Data of Vestibular and Postural Function in Danish Children","Vestibular ASsessment In Children - Balance Function in Normal Children and Specific Risk Groups (VASIC)","VASIC","Inclusion Criteria:\n\n* Children in the age of 6 months -10 years\n* Normal hearing\n* No history of dizziness or balance problems\n* Written informed consent from the parents.\n\nExclusion Criteria:\n\n* Premature birth\n* Existing or previous inner ear disease(s) or previous inner ear surgery\n* Cholesteatoma or previous middle ear surgery\n* Known or previous vestibular disorder (Vestibular schwannoma, Mb Meniere, vestibular neuritis or other known)\n* Delayed gross motor development evaluated through milestones.\n* Visual impairment to such a degree that the child is not able to maintain fixation on a dot one meter away.\n* Congenital nystagmus\n* Compromised eye muscle mobility\n* A diagnose of any neurological disease.\n* A diagnose of any psychiatric disease.\n* VEMP-electrode allergy\n* History of symptomatic head or neck trauma\n* Prescription of medicine which alters vestibular outputs (for instance sedative antihistamines)","6 Months","10 Years",{"count":286,"type":21},90,"The goal of this age-based cohort study is to provide normative data of vestibular function in the general Danish pediatric population. Thus, the investigators will be able to compare patient data with norms, allowing for more precise diagnostics. The participants will be children in the age of 6 months to 10 years, without any known hearing or balance problems. The test protocol consists of questionnaires, hearing screening and vestibular and postural assessments.",[289,290],"Children, Only","Vestibular Function",[292,293,98,294,295,296,297,298,299],"Vestibular dysfunction","Balance problem","Dizziness","Vestibular assessment","video Head Impulse Test","Vestibular Evoked Myogenic Potential","Computerized Dynamic Posturography","Quality of life","2025-08-21",{"date":302,"type":38},"2025-08-26",{"date":304,"type":38},"2025-06-01",{"date":306,"type":21},"2027-12",{"name":44,"class":45},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":280,"acronym":281,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":283,"maxAge":284,"enrollmentInfo":314,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":46},"100533737","vestibular-and-postural-function-in-children-suspected-of-balance-disorders-100533737","NCT06229704","Vestibular and Postural Function in Children Suspected of Balance Disorders","Inclusion Criteria:\n\n* Children in the age of 6 months to 10 years\n* Delayed gross motor development and\u002For dizziness\u002Fbalance problems.\n* Written informed consent from the parents.\n\nExclusion Criteria:\n\n* Visual impairment to such a degree that the child is not able to maintain fixation on a dot one meter away.\n* Congenital nystagmus\n* Compromised eye muscle mobility\n* VEMP-electrode allergy\n* History of symptomatic head or neck trauma\n* Prescription of medicine which alters vestibular outputs (for instance sedative antihistamines)",{"count":315,"type":21},30,"The goal of this prospective cohort study is to investigate the vestibular function in children suspected of balance disorders, and to follow up on their balance progressions after rehabilitation. The main hypothesis of the study is that delayed gross motor development and symptoms of dizziness and balance problems in some children are caused by vestibular dysfunction. The investigators expect that early detection and rehabilitation by a physiotherapist will improve the balance ability for the child. The participants will be children in the age of 6 months to 10 years with delayed gross motor development and\u002For with dizziness\u002Fbalance problems. The test protocol consists of questionnaires, hearing screening and vestibular and postural assessments.",[289,318,319,320],"Vestibular Disorder","Vestibular Function Disorder","Development Delay",[292,293,98,294,295,296,297,298,322],"Delayed gross motor development",{"date":302,"type":38},{"date":325,"type":38},"2025-08-20",{"date":327,"type":21},"2028-12",{"name":44,"class":45},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":280,"acronym":281,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":335,"maxAge":284,"enrollmentInfo":336,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":345,"locationsCount":46},"100533738","vestibular-and-postural-function-in-an-unselected-group-of-children-with-sensorineural-hearing-loss-100533738","NCT06229717","Vestibular and Postural Function in an Unselected Group of Children With Sensorineural Hearing Loss","Inclusion Criteria:\n\n* Children in the age of 3-10 years\n* Uni- or bilateral sensorineural hearing loss \\> 20 dB bone conduction pure tone average measured at frequencies 0.5, 1, 2, 4 kHz\n* Written informed consent from the parents.\n\nExclusion Criteria:\n\n* Previous inner ear surgery\n* Visual impairment to such a degree that the child is not able to maintain fixation on a dot one meter away.\n* Congenital nystagmus\n* Compromised eye muscle mobility\n* VEMP-electrode allergy\n* History of symptomatic head or neck trauma\n* Prescription of medicine which alters vestibular outputs (for instance sedative antihistamines)","3 Years",{"count":337,"type":21},48,"The goal of this prospective cohort study is to investigate the vestibular function in children with unilateral or bilateral sensorineural hearing loss. The main hypothesis of the study is that abnormal vestibular test results will be found in 20-30 % of the children with sensorineural hearing loss. The participants will be children in the age of 3-10 years with sensorineural hearing loss. The test protocol consists of questionnaires and vestibular and postural assessments.",[289,318,290,176],[292,293,98,341,294,295,296,297,298,299],"Hearing Loss",{"date":302,"type":38},{"date":325,"type":38},{"date":327,"type":21},{"name":44,"class":45},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":363,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":46},"100582758","effects-of-exogenous-ketosis-on-proteinuria-and-renal-function-100582758","NCT06867471","Effects of Exogenous Ketosis on Proteinuria and Renal Function","Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Patients with Polycystic Kidney Disease","KETO-CKD","Inclusion Criteria\n\nStudy A (patients with CKD):\n\n* ACR \\> 200 mg\u002Fg \\\u003C3000 mg\u002Fg\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nStudy B (patients with PKD):\n\n* Prior diagnose with PKD\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nExclusion Criteria (Study A+B)\n\n* Diabetes Mellitus type 1\n* Heart Failure\n* Liver Disease\n* Kidney transplant\n* Malignant diseases (except skin cancer)\n* Recent acute myocardial infarction (AMI), apoplexia\u002Ftransient ischemic attack (TIA) (within 3 months of inclusion)\n* Pregnancy or breast feeding\n* Alcohol or drug abuse\n* Periodic fasting within four weeks of inclusion\n* Routinely intake of ketogenic diet within four weeks of inclusion\n* Treatment with nitrate",{"count":355,"type":21},43,[24],"A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.",[359,360,361,362],"Renal Insufficiency, Chronic","Polycystic Kidney Diseases","Proteinuria","Ketosis",[364,365,366,362,361,367],"Kidney physiology","Glomerular Filtration Rate","Chronic Kidney disease","Natriuresis","2025-03-06",{"date":370,"type":38},"2025-03-10",{"date":372,"type":38},"2024-09-11",{"date":374,"type":21},"2025-12",{"name":44,"class":45},""]